Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:52:55.820Z.
Calculation as of: 2026-10-06T18:52:55.820Z.
Quote observation: 2026-10-06T18:50:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4fd5d7af3ee6af72921bc315e5ba82b5757c441ca2a41ed9c1ba6c6f3afb8810
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Regencell Bioscience Holdings Limited
Market Cap
$3.88B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.05B
Price/FCF Ratio
N/A
TTM Avg
19.54
3Y Avg
224.11
5Y Avg
224.11
Market Cap
$3.55B
Price/FCF Ratio
91.00
TTM Avg
158.72
3Y Avg
191.31
5Y Avg
191.31
Market Cap
$3.53B
Price/FCF Ratio
N/A
TTM Avg
15.00
3Y Avg
15.00
5Y Avg
15.00
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited (RGC) | $3.88B | N/A | N/A | N/A | N/A |
| ICU Medical, Inc. (ICUI)vs › | $3.95B | 25.84 | 43.24 | 35.19 | 47.16 |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.03B | N/A | N/A | N/A | N/A |
| AbCellera Biologics Inc. (ABCL)vs › | $4.05B | N/A | 19.54 | 224.11 | 224.11 |
| LivaNova PLC (LIVN)vs › | $4.13B | 27.83 | 22.61 | 65.13 | 62.83 |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 21.49 | 27.61 | 43.56 | 61.80 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | 91.00 | 158.72 | 191.31 | 191.31 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.53B | N/A | 15.00 | 15.00 | 15.00 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.49B | N/A | 12.06 | 12.04 | 12.04 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
